Merck will continue to search out more acquisitions after its $11 billion purchase of biotech firm Acceleron Pharma, the company’s CEO told STAT in an interview Thursday.
But the CEO, Rob Davis, said he also believes that investors have not yet come to realize the value of the experimental drugs Merck is developing.
“We will be appropriately aggressive about our business development,” Davis said. “And we’re also going to continue to make sure we strongly invest in our internal pipeline. We’re going to do both.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
